Preview

Russian Journal of Gastroenterology, Hepatology, Coloproctology

Advanced search

Efficacy of Alginate-Antacid Medication in the Treatment of Patients with Gastroesophageal Reflux Disease

https://doi.org/10.22416/1382-4376-2018-28-5-46-58

Full Text:

Abstract

Aim. In this work, we aim to analyze the efficacy of treatment for heartburn and pathological gastroesophageal refluxes (GERs) using alginate-antacid medication. We assess the dynamics of inflammatory process in patients with gastroesophageal reflux disease (GERD) treated with alginate-antacid medication used at conventional dosage, both as a monotherapy and as part of a GERD combination therapy. To this end, we set out to confirm the formation of the layer of unbuffered acidic gastric juice over the gastric chyme after eating, as well as to determine the acidneutralizing effect of alginate-antacid medication upon its interaction with the acidic contents of the stomach.

Materials and methods. 36 case records of GERD patients were analyzed (20 women and 16 men, mean age 47.03 years old). All patients were asked to report the heartburn intensity (according to a Likert scale) prior and during the treatment. They were subjected to esophagogastroduodenoscopy (EGD) and 24-hour pH impedance monitoring prior and on the 14th day of treatment. Before treatment, high-resolution esophageal manometry was performed to exclude the esophageal hiatal hernia (EHH) and to determine the upper and lower boundaries of the lower esophageal sphincter (LES). Group 1 included patients with non-erosive reflux disease (NERD), who were receiving monotherapy with alginate-antacid. Patients with the I-II degree of erosive esophagitis (EE) comprised groups 2 and 3, respectively, and were receiving proton pump inhibitor (PPI) monotherapy and PPI and alginate-antacid medication combination therapy, respectively. In group 1, 10 patients were examined using a probe pull-through technique with the purpose of determining pH levels in the cardiac stomach, in the area of the gastro-esophageal junction and in the esophagus at a level of 5 cm above the LES, both in the fasting state and after eating, as well as prior and after using alginate-antacid preparations. 

Results. On the third day of treatment, a complete heartburn relief was observed in 5 (41.6 %) patients of the NERD patient group (group 1), who were receiving a monotherapy with alginate-antacid medication. Heartburn relief was achieved in 3 EE (25 %) and 6 EE patients (50 %) following a PPI treatment course and a PPI and alginate-antacid medication treatment course, respectively. On the 5th day of treatment, heartburn was neutralized in 8 (66.7 %), 7 (58.3 %) and 9 (75 %) patients, with these numbers having risen to 10 (83.3 %), 9 (75 %) and 10 (83.3 %) patients (in the respective groups) on the 14th day. Before treatment, no significant differences in the heartburn intensity were identified between the groups. On the 3rd day of treatment, a significant difference was observed in the dynamics of heartburn intensity between groups 1 – 2 and 2 – 3 (p < 0.05), with this difference having disappeared by the 5th day. According to EGD in the NERD group, inflammation were eliminated in 10 (83.3 %) patients. In EE patients of the 2nd and 3rd groups, the healing of erosions was confirmed in 8 (66.7 %) and 10 (83.3 %) patients, respectively. In general, during the 24-hour pH impedance monitoring, pathological acid, weakly acid and non acid GERs were diagnosed in 28 (77.8 %), 15 (41.7 %) and 9 (25 %) patients, respectively. Under a course of alginate-antacid medication monotherapy, acid reflux was eliminated in 100 % of NERD patients. Among ERD patients undergoing PPI monotherapy, acidic GERs were eliminated in 9 (75 %) patients; however, the addition of alginate-antacid medication to a PPI treatment regimen allowed this result to be increased to 91.7 %. Weakly acid GERs were eliminated in 70 % and 33.3 % of patients in groups 1 and 2, respectively. In group 3, where patients were receiving a PPI and alginate-antacid medication combination treatment, weakly acid GERs were eliminated in 75 % of cases. Non acid refluxes were eliminated in groups 1 and 3 in 50 %, and in 2 – in 33.3 % of cases. When pulling the probe in the fasting state, a sharp change in pH values from acid (0.9–2 units) to weakly acid, and then non acid (5.5–7.6 units), was observed in 100 % of cases. After a meal and before the administration of alginate-antacid medication, the layer of unbuffered acidic gastric juice (pH < 2) was detected in the proximal stomach of 9 patients (90 %). After administration of alginate-antacid medication, the pH ranged from 6.1 to 7.7 units in 7 (70 %) patients, and increased to 4.2 units in 3 people (30 %).

Conclusions. The inclusion of alginate-antacid medication into treatment schemes for managing ERD patients significantly increases its effectiveness, reliably increasing the rate of the onset of the clinical effect. alginate-antacid medication is shown to be an effective monotherapy for NERD. An important advantage of alginate-antacid medication in the treatment of GERD postprandial symptoms consists in its ability to neutralize and displace distally the layer of unbuffered acidic gastric juice, which forms above the chyme surface. 

About the Authors

O. A. Storonova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Department of Propedeutics of Internal Diseases, V.H. Vasilenko Clinic of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology.
Russian Federation

Cand. Sci. (Med.), Physician, Department of Functional Diagnostics of the V.H. Vasilenko Clinic  of Propaedeutics of Internal Diseases, Gastroenterology and  Hepatology, I.M. Sechenov First Moscow State Medical University (Sechenov University).  

119991, Moscow, Pogodinskaya str., 1, building 1.  



A. S. Trukhmanov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Department of Propedeutics of Internal Diseases, V.H. Vasilenko Clinic of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology.
Russian Federation

 Dr. Sci. (Med.), Prof., Department of Propedeutics of Internal Diseases of the Medical Faculty, I.M. Sechenov First Moscow State Medical University  (Sechenov University).  

119991, Moscow, Pogodinskaya str., 1, building 1.  



V. T. Ivashkin
I.M. Sechenov First Moscow State Medical University (Sechenov University), Department of Propedeutics of Internal Diseases, V.H. Vasilenko Clinic of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology.
Russian Federation

 Dr. Sci. (Med.), RAS Academician,  Prof., Departmental Head, Head of the V.H. Vasilenko Clinic  of Propaedeutics of Internal Diseases, Gastroenterology and  Hepatology, I.M. Sechenov First Moscow State Medical University (Sechenov University).  

119991, Moscow, Pogodinskaya str., 1, building 1.  



References

1. Yevsyutina Yu.V., Trukhmanov A.S. New opinion on the issue of proton pump inhibitor-refractory gastroesophageal reflux disease. Rus J Gastroenterol Hepatol Coloproctol. 2014;24(5):4–9 (In Rus.).

2. Kaybysheva V.O., Trukhmanov A.S., Ivashkin V.T. Gastroesophageal reflux disease, resistant to proton pump inhibitors. Rus J Gastroenterol Hepatol Coloproctol. 2011;21(4):4–13 (In Rus.).

3. Bordin D.S. “Acid pocket” as a pathogenetic basis and therapeutic target in gastroesophageal reflux disease. Ther Arch. 2014;86(2):76–81 (In Rus.).

4. Steingoetter A., Sauter M., Curcic J., Liu D., Menne D., Fried M., Fox M., Schwizer W. Volume, distribution and acidity of gastric secretion on and off proton pump inhibitor treatment: a randomized double-blind controlled study in patients with gastro-esophageal reflux disease (GERD) and healthy subjects. BMC Gastroenterology. 2015;15:111–21.

5. Clarke A.T., Wirz A.A., Seenan J.P., Manning J.J., Gillen D., McColl K.E. Paradox of gastric cardia: it becomes more acidic following meals while the rest of stomach becomes less acidic. Gut. 2009;58(7):904–9.

6. Fletcher J., Wirz A., Young J., Vallance R., McColl K.E. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology. 2001;121(4):775–83.

7. Kahrilas P.J., McColl K., Fox M., O’Rourke L., Sifrim D., Smout A.J., Boeckxstaens G. The acid pocket: a target for treatment in reflux disease?. Am J Gastroenterol. 2013;108(7):1058–64.

8. Likert R. Archives of Psychology. Vol. 22. New York: The Science Press; 1932. A technique for the measurement of attitudes; No 140. p. 55.

9. Ivashkin V.T., Mayev I.V., Trukhmanov A.S., Baranskaya Ye.K., Dronova О.B., Zayratyants О.V., et al. Diagnostics and treatment of gastroesophageal reflux disease: clinical guidelines of the Russian gastroenterological association. Rus J Gastroenterol Hepatol Coloproctol. 2017;27(4):75–95 (In Rus.).

10. Johnson L.F., DeMeester T.R. Development of 24-hour intraesophageal pH monitoring composite scoring system. Esophageal Disorders: Pathophysiology and Therapy. Ed. by T.R. DeMeester, D.B. Skinner. N.Y.: Raven Press; 1985. P. 561–70.

11. Gyawali C.P., Kahrilas P.J., Savarino E., Zerbib F., Mion F., Smout A.J.P.M., et al. Modern diagnosis of GERD: the Lyon Consensus. Gut Published Online First: 03 February 2018. DOI: 10.1136/gutjnl-2017-314722

12. Roman S., Gyawali C. P., Savarino E., Yadlapati R., Zerbib F., Wu J., et al. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil. 2017;e13067. DOI: 10.1111/nmo.13067

13. Kao C.H., Ho Y.J., Chang Lai S.P., Liao K.K. Evidence for decreased salivary function in patients with reflux esophagitis. Digestion. 1999;60(3):191–5.

14. Ivashkin V.T., Maev I.V., Trukhmanov A.S. Reference book on instrumental studies and interventions in gastroenterology. M.: GEOTAR Media, 2015; 560 p. (In Rus.).

15. Storonova A.O., Trukhmanov A.S., Ivashkin V.T. Whether pH-metry and investigation of esophageal motor function are necessary for diagnosis and choice of therapy for us today?. Rus J Gastroenterol Hepatol Coloproctol. 2010;20(2):73–83 (In Rus.).

16. Trukhmanov A.S., Storonova O.A., Ivashkin V.T. Clinical impact of 24-hour pH-metry in esophageal and stomach diseases diagnostics and pharmacological drugs efficacy testing. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(6):55–68 (In Rus.).

17. Trukhmanov A.S., Kaybysheva V.O., Storonova O.A., Ivashkin V.T. Intraesophageal рНimpedance measurement in diagnostics of gastroesophageal reflux disease. Clin Perspectiv Gastroenterol Hepatol. 2014;1:16–25 (In Rus.).

18. Bredenoord A.J., Weusten B.L., Timmer R., Conchillo J.M., Smout A.J. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. Am J Gastroenterol. 2006;101(3):453–9.

19. Bredenoord A.J. Impedance-pH monitoring: new standard for measuring gastro-oesophageal reflux. Neurogastroenterol Motil. 2008;20(5):434–9.

20. Savarino E., Zentilin P., Tutuian R., et al. The role of nonacid reflux in NERD: lessons learned from impedancepH monitoring in 150 patients off therapy. Am J Gastroenterol. 2008;103:2685–2693.

21. Uspensky Yu.P., Baryshnikova N.V., Pakhomova I.G. Clinical prospects of application of alginate-based agents in the treatment of gastroesophageal reflux disease. Rus J Gastroenterol Hepatol Coloproctol. 2009;19(2):79–84 (In Rus.).

22. Kwiatek M.A., Roman S., Fareeduddin A., Pandolfino J.E., Kahrilas P.J. An alginate-antacid formulation (Gaviscon Double Action Liquid®) can eliminate the postprandial «acid pocket» in symptomatic GERD patients. Aliment Pharmacol Ther. 2011;34(1):59–66.

23. Rohof W.O., Bennink R.J., Smout A.J., Thomas E., Boeckxstaens G.E. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2013 Dec;11(12):1585–91.

24. Ivashkin V.T. The importance of radiotelemetric studies of intragastric and intraduodenal pH to assess the effectiveness of the action of antacids and atropine in patients with chronic diseases of the stomach and duodenum: PhD Thesis of Candidate of Medical Sciences. L., 1970. 187 p. (In Rus.).

25. De Ruigh A., Roman S., Chen J., Pandolfino J.E., Kahrilas P.J. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling postprandial esophageal acid exposure in GERD patients; a double-blind crossover study. Aliment Pharmacol Ther. 2014;40(5):531–7.

26. Ivashkin V.T., Maev I.V., Trukhmanov A.S., Storonova O.A., Kucheryavyi Yu.A., Barkalova E.V., Ovsepyan M.A., Andreev D.N., Paraskevova A.V., Rumyantseva D.E. High resolution manometry and new classification of esophageal motility disorders. Ther. Arch. 2018;90(5):93–100. (In Rus.).

27. Storonova O.A., Trukhmanov A.S., Ivashkin V.T. High-resolution manometry in clinical practice: analysis of esophageal motor function according to Chicago classification. Rus J Gastroenterol Hepatol Coloproctol. 2018;28(2):11–23 (In Rus.).

28. Trukhmanov A.S., Storonova O.A., Ivashkin V.T. Clinical value of motor function of digestive system investigation: past, present and future. Rus J Gastroenterol Hepatol Coloproctol. 2013;23(5):4–14 (In Rus.).

29. Leiman D.A., Riff B.P., Morgan S., Metz D.C., Falk G.W., French B., Umscheid C.A., Lewis J.D. Alginate therapy is effective treatment for gastroesophageal reflux disease symptoms: a systematic review and metaanalysis. Dis Esophagus. 2017;30(2):1–8.

30. Reimer C., Lødrup A.B., Smith G., Wilkinson J., Bytzer P. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther. 2016;43(8):899–909.

31. Sun J., Yang C., Zhao H., Zheng P., Wilkinson J., Yuan B. Ng & Y. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China. Aliment Pharmacol Ther. 2015;42:845–54.

32. Lindow S.W., Regnéll P., Sykes J., Little S. An openlabel, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy. Int J Clin Pract. 2003;57(3):175–9.


Review

For citations:


Storonova O.A., Trukhmanov A.S., Ivashkin V.T. Efficacy of Alginate-Antacid Medication in the Treatment of Patients with Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(5):46-58. (In Russ.) https://doi.org/10.22416/1382-4376-2018-28-5-46-58

Views: 2040


ISSN 1382-4376 (Print)
ISSN 2658-6673 (Online)